Immunohistochemical analysis of the fibronectin expression and its prognostic value in patients with laryngeal cancer;Analiza immunohistochemiczna ekspresji fibronektyny i jej znaczenie prognostyczne u chorych na raka krtani

Otolaryngologia Polska

Volumn 60, Issue 5, 2006, Pages 697-702

  Pietruszewska, Wioletta ^a   Kobos, Józef ^b   Bojanowska Poźniak, Katarzyna ^a   Durko, Marcin ^b   Gryczyński, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NONE

Author keywords

Fibronectin; Laryngeal squamous cell carcinoma; Prognostic factor

Indexed keywords

FIBRONECTIN; TUMOR MARKER;

ARTICLE; CANCER INVASION; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX TUMOR; MALE; METABOLISM; METHODOLOGY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; FEMALE; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34047212875     PISSN: 00306657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Antonelli AR, Nicolai P, Cappiello J. Basement membrane components in normal, dysplastic, neoplastic laryngeal tissue and metastatic lymph nodes. Acta Otolaryngol (Stockh) 1991; 111: 437-443.
2. Birchler MT, Milisavlijevic D, Pfaltz M. Expression of extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 2003; 113: 1231-1237.
3. Courey M, Scott M, Shohet J. Immunohistochemical characterization of benign laryngeal lesions. Ann Otol Rhinol Laryngol 1996; 105: 525-531.
4. Fuller GM, Shields D. Podstawy molekularne biologii komórki. Warszawa: 2000.
5. Gray S, Hammond E, Hanson D. Benign pathologic responses of the larynx. Ann Otol Rhinol Laryngol 1995; 104: 13-18.
6. Hagedorn H, Schriner M, Wiest I. Defective basement membrane in laryngeal carcinomas with heterogenous loss of distinct components. Hum Pathol 1998; 5: 447-454.
7. Ioachim E, Charchanti A, Briasoulis E. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumor invasion and progression. Eur J Cancer 2002; 38: 2362-2370.
8. Kwiatkowska D, Kwiatkowska-Korczak J. Adhezyjne glikoproteiny macierzy zewnatrzkomórkowej. Post Hig Med Dośw 1999; 53(1): 55-74.
9. Loridon-Rosa B, Viehl P, Cuadrato C. Comparative distribution of fibronectin and vitronectin in human brest and colon carcinomas. Am J Clin Pathol 1988; 90: 7-16.
10. Mandel U, Therkildsen M, Reibel J. Cancer-assiociated changes in glicosylation of fibronectin. AMPIS 1992; 100: 817-826.
11. Moro L, Colombi M, Molinari Tosatti MP. Study of fibronectin mRNA in human laryngeal and ectocervical carcinomas by in situ hybridization and image analysis. Int J Cancer 1992; 51: 692-697.
12. Nejjari M, Anderson W, Pourreyorn C. The role of fibroblasts in the modulation of integrin-dependent interactions between the gastric cell line HGt-1 and fibronectin. Int J Cancer 2004; 112: 560-569.
13. Pietruszewska W, Kobos J, Gryczyński M. Ekspresja białka beta-katenina w raku płaskonabłonkowym krtani. Otolaryng Pol 2004; 58(5): 949-956.
14. Przybysz M, Katnik-Prastowska I. Wielofunkcyjność fibronektyny. Post Hig Med Dośw 2001; 55(5): 699-713.
15. Santimaria M, Moscatelli G, Viale GL. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patient with cancer. Clin Cancer Res 2003; 9: 571-579.
16. Stenman S, Vaheri A. Fibronectin in human solid tumors. Int J Cancer 1981; 27: 427-435.
17. Thibeault SL, Gray S, Ma W. Genotypic and fenotypic expression of vocal fold polyps and Reinke's edema: a preliminary study. Ann Otol Rhinol Laryngol 2002; 111: 302-309.